Sodium-dependent dopamine transporter (SLC6A3) (DAT)

The Sodium-dependent dopamine transporter (DAT) is a transmembrane protein primarily expressed in the central nervous system, where it mediates the reuptake of dopamine from the synaptic cleft into presynaptic neurons [UniProt: P23975]. This process is the principal mechanism for terminating dopaminergic signaling, thereby regulating the spatial and temporal dynamics of dopamine in the brain [PubMed: 25637201]. DAT is essential for maintaining dopamine homeostasis and influences motor control, reward-seeking behavior, and cognitive functions [StatPearls: NBK538350]. Dysfunctional dopamine transport is a hallmark of several neurological and psychiatric disorders, most notably Parkinson's disease, where DAT density is significantly reduced, and ADHD, where DAT levels may be elevated [PubMed: 25637201]. Consequently, DAT is a major therapeutic target for stimulants used to treat ADHD and narcolepsy, as well as a primary site of action for addictive substances like cocaine and amphetamines [PubChem: SLC6A3]. Pharmacological agents targeting DAT typically act as reuptake inhibitors or substrate-mediated releasers, increasing the concentration of extracellular dopamine [PubMed: 25637201]. Monitoring DAT density through neuroimaging serves as a critical diagnostic tool for neurodegenerative conditions [StatPearls: NBK538350].

Other names

SLC6A3DAT1Dopamine active transporterSolute carrier family 6 member 3DAT

Inhibition of dopamine reuptake from the synaptic cleft into the presynaptic neuron by binding to the transporter, or induction of substrate-mediated dopamine release through the transporter, thereby increasing extracellular dopamine levels [PubMed: 25637201].